2026 Q3 - tulosraportti
UUTTA
7 päivää sitten
‧1 t 3 min
3,75 DKK/osake
Viimeisin osinko
4,29%Tuotto/v
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 5 | ||
| 6 000 | ||
| 752 | ||
| 6 000 | ||
| 2 000 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 3.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 4.11. | ||
2026 Q2 - tulosraportti 5.8. | ||
2026 Q1 - tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 - tulosraportti 4.2. |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·1 t sittenWegovy tablets called a flop – but important information is missing The German newspaper WirtschaftsWoche has called the launch of Novo Nordisk's Wegovy tablets in Germany a flop. Handelsblatt, which belongs to the same media group, has subsequently republished the article. But the article omits a crucial piece of information: Novo Nordisk stated as early as November 4 that approximately 100,000 packs of Wegovy tablets had been sold in Germany during the first six weeks. Most buyers were new patients who had not previously received GLP-1 treatment. The article's comparison with injection treatment is also problematic: * September was the first month on the market for Wegovy tablets. * The figures for injections include both Wegovy and Ozempic. * The claim that dosage requirements are slowing down sales is not documented. * German sales figures are compared with US prescription figures, which are not directly comparable. At the same time, Novo Nordisk's figures show that Wegovy tablets have achieved approximately 90 % of the market for oral obesity treatments in the UK and 80 % in the United Arab Emirates. A question of journalistic credibility It is also worth noting that Eli Lilly – Novo Nordisk's direct competitor – was an official partner at both Handelsblatt's Pharma 2025 conference and Health 2026 conference in Berlin on November 3–4. These commercial connections were not mentioned in the article. This does not prove that Lilly has influenced the journalism, but it raises a relevant question about transparency and conflicts of interest. When a media outlet criticizes a pharmaceutical company while having commercial ties to the company's biggest competitor, readers should have the right to know these relationships.
Just for info. 75.4% of the men and 58.9% of the women. In Germany, 75.4% of the men and 58.9% of the women are overweight, which is a significantly higher proportion than in many other European countries. This places Germany at the top of the list of European countries with the highest proportion of overweight individuals.- ·2 t sitten · MuokattuNice US close at 41,10 dollars. Price 277,00 Stable steady development all evening along with nice volume. Exciting day tomorrow. No doubt, US is buying up👍 Wonder if they are also aware that they miscalculated with their "liquidation" of Cagrisema, which may soon be on the market.
Interesting that now, several times over the last few days, it is the US that has traded the price up towards the close. At the same time, the dollar continues upwards, which of course is good for the profit. - ·2 t sittenNovo Nordisk is launching weekly insulin in Thailand amidst increased focus on cardiovascular diseases and diabetes. On November 9, 2026, Novo Nordisk announced the launch of the long-acting insulin icodec in Thailand. The treatment enables patients to reduce the number of basal insulin injections from 365 to approximately 52 per year – that is, from daily to weekly injections. Thailand has a significant disease burden with an estimated 6.36 million adults with diabetes in 2024, of which approximately 2.12 million are not yet diagnosed. At the same time, around 17% of the adult population lives with obesity. On November 11, Novo Nordisk Thailand's commitment to early detection and treatment of diabetes, cardiovascular, and kidney diseases was also highlighted in Thai media. Chronic diseases are estimated to cost Thailand around 1,600 billion baht annually. Novo Nordisk Thailand's Managing Director, Cihan Serdar Kizilcik, is also Vice Chairman of the Pharmaceutical Research and Manufacturers Association (PReMA). The organization works for increased national and international cooperation on screening, diagnosis, and access to innovative treatments.
·3 t sittenA10A must be on parental leave with all that time in here 🤣 probably also has 100% in the stock. Crossing fingers for you my friend ❤️
On parental leave. And that presumably requires a woman. And that one is not sterile.- ·3 t sittenBalancing right now around 41 dollars in US. 👍
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q3 - tulosraportti
UUTTA
7 päivää sitten
‧1 t 3 min
3,75 DKK/osake
Viimeisin osinko
4,29%Tuotto/v
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·1 t sittenWegovy tablets called a flop – but important information is missing The German newspaper WirtschaftsWoche has called the launch of Novo Nordisk's Wegovy tablets in Germany a flop. Handelsblatt, which belongs to the same media group, has subsequently republished the article. But the article omits a crucial piece of information: Novo Nordisk stated as early as November 4 that approximately 100,000 packs of Wegovy tablets had been sold in Germany during the first six weeks. Most buyers were new patients who had not previously received GLP-1 treatment. The article's comparison with injection treatment is also problematic: * September was the first month on the market for Wegovy tablets. * The figures for injections include both Wegovy and Ozempic. * The claim that dosage requirements are slowing down sales is not documented. * German sales figures are compared with US prescription figures, which are not directly comparable. At the same time, Novo Nordisk's figures show that Wegovy tablets have achieved approximately 90 % of the market for oral obesity treatments in the UK and 80 % in the United Arab Emirates. A question of journalistic credibility It is also worth noting that Eli Lilly – Novo Nordisk's direct competitor – was an official partner at both Handelsblatt's Pharma 2025 conference and Health 2026 conference in Berlin on November 3–4. These commercial connections were not mentioned in the article. This does not prove that Lilly has influenced the journalism, but it raises a relevant question about transparency and conflicts of interest. When a media outlet criticizes a pharmaceutical company while having commercial ties to the company's biggest competitor, readers should have the right to know these relationships.Just for info. 75.4% of the men and 58.9% of the women. In Germany, 75.4% of the men and 58.9% of the women are overweight, which is a significantly higher proportion than in many other European countries. This places Germany at the top of the list of European countries with the highest proportion of overweight individuals.
- ·2 t sitten · MuokattuNice US close at 41,10 dollars. Price 277,00 Stable steady development all evening along with nice volume. Exciting day tomorrow. No doubt, US is buying up👍 Wonder if they are also aware that they miscalculated with their "liquidation" of Cagrisema, which may soon be on the market.Interesting that now, several times over the last few days, it is the US that has traded the price up towards the close. At the same time, the dollar continues upwards, which of course is good for the profit.
- ·2 t sittenNovo Nordisk is launching weekly insulin in Thailand amidst increased focus on cardiovascular diseases and diabetes. On November 9, 2026, Novo Nordisk announced the launch of the long-acting insulin icodec in Thailand. The treatment enables patients to reduce the number of basal insulin injections from 365 to approximately 52 per year – that is, from daily to weekly injections. Thailand has a significant disease burden with an estimated 6.36 million adults with diabetes in 2024, of which approximately 2.12 million are not yet diagnosed. At the same time, around 17% of the adult population lives with obesity. On November 11, Novo Nordisk Thailand's commitment to early detection and treatment of diabetes, cardiovascular, and kidney diseases was also highlighted in Thai media. Chronic diseases are estimated to cost Thailand around 1,600 billion baht annually. Novo Nordisk Thailand's Managing Director, Cihan Serdar Kizilcik, is also Vice Chairman of the Pharmaceutical Research and Manufacturers Association (PReMA). The organization works for increased national and international cooperation on screening, diagnosis, and access to innovative treatments.
- ·3 t sittenA10A must be on parental leave with all that time in here 🤣 probably also has 100% in the stock. Crossing fingers for you my friend ❤️On parental leave. And that presumably requires a woman. And that one is not sterile.
- ·3 t sittenBalancing right now around 41 dollars in US. 👍
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 5 | ||
| 6 000 | ||
| 752 | ||
| 6 000 | ||
| 2 000 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 3.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 4.11. | ||
2026 Q2 - tulosraportti 5.8. | ||
2026 Q1 - tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 - tulosraportti 4.2. |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q3 - tulosraportti
UUTTA
7 päivää sitten
‧1 t 3 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 3.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 4.11. | ||
2026 Q2 - tulosraportti 5.8. | ||
2026 Q1 - tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 - tulosraportti 4.2. |
Tuotteita joiden kohde-etuutena tämä arvopaperi
3,75 DKK/osake
Viimeisin osinko
4,29%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·1 t sittenWegovy tablets called a flop – but important information is missing The German newspaper WirtschaftsWoche has called the launch of Novo Nordisk's Wegovy tablets in Germany a flop. Handelsblatt, which belongs to the same media group, has subsequently republished the article. But the article omits a crucial piece of information: Novo Nordisk stated as early as November 4 that approximately 100,000 packs of Wegovy tablets had been sold in Germany during the first six weeks. Most buyers were new patients who had not previously received GLP-1 treatment. The article's comparison with injection treatment is also problematic: * September was the first month on the market for Wegovy tablets. * The figures for injections include both Wegovy and Ozempic. * The claim that dosage requirements are slowing down sales is not documented. * German sales figures are compared with US prescription figures, which are not directly comparable. At the same time, Novo Nordisk's figures show that Wegovy tablets have achieved approximately 90 % of the market for oral obesity treatments in the UK and 80 % in the United Arab Emirates. A question of journalistic credibility It is also worth noting that Eli Lilly – Novo Nordisk's direct competitor – was an official partner at both Handelsblatt's Pharma 2025 conference and Health 2026 conference in Berlin on November 3–4. These commercial connections were not mentioned in the article. This does not prove that Lilly has influenced the journalism, but it raises a relevant question about transparency and conflicts of interest. When a media outlet criticizes a pharmaceutical company while having commercial ties to the company's biggest competitor, readers should have the right to know these relationships.Just for info. 75.4% of the men and 58.9% of the women. In Germany, 75.4% of the men and 58.9% of the women are overweight, which is a significantly higher proportion than in many other European countries. This places Germany at the top of the list of European countries with the highest proportion of overweight individuals.
- ·2 t sitten · MuokattuNice US close at 41,10 dollars. Price 277,00 Stable steady development all evening along with nice volume. Exciting day tomorrow. No doubt, US is buying up👍 Wonder if they are also aware that they miscalculated with their "liquidation" of Cagrisema, which may soon be on the market.Interesting that now, several times over the last few days, it is the US that has traded the price up towards the close. At the same time, the dollar continues upwards, which of course is good for the profit.
- ·2 t sittenNovo Nordisk is launching weekly insulin in Thailand amidst increased focus on cardiovascular diseases and diabetes. On November 9, 2026, Novo Nordisk announced the launch of the long-acting insulin icodec in Thailand. The treatment enables patients to reduce the number of basal insulin injections from 365 to approximately 52 per year – that is, from daily to weekly injections. Thailand has a significant disease burden with an estimated 6.36 million adults with diabetes in 2024, of which approximately 2.12 million are not yet diagnosed. At the same time, around 17% of the adult population lives with obesity. On November 11, Novo Nordisk Thailand's commitment to early detection and treatment of diabetes, cardiovascular, and kidney diseases was also highlighted in Thai media. Chronic diseases are estimated to cost Thailand around 1,600 billion baht annually. Novo Nordisk Thailand's Managing Director, Cihan Serdar Kizilcik, is also Vice Chairman of the Pharmaceutical Research and Manufacturers Association (PReMA). The organization works for increased national and international cooperation on screening, diagnosis, and access to innovative treatments.
- ·3 t sittenA10A must be on parental leave with all that time in here 🤣 probably also has 100% in the stock. Crossing fingers for you my friend ❤️On parental leave. And that presumably requires a woman. And that one is not sterile.
- ·3 t sittenBalancing right now around 41 dollars in US. 👍
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 5 | ||
| 6 000 | ||
| 752 | ||
| 6 000 | ||
| 2 000 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt